Participated · Equity · Jun 2025

Perci Health operates an AI-powered, multidisciplinary virtual cancer clinic that integrates digital tools with NHS-trained specialist clinicians to deliver personalised cancer prevention, treatment navigation, symptom management and survivorship care. The company has a network of over 85 NHS-trained specialists and emphasizes a predominantly female leadership and board. Founded in 2020, Perci aims to expand its virtual clinic across the UK and deepen partnerships with insurers, employers, the NHS and charities to improve outcomes and reduce costs. The new funding is intended to scale the platform’s reach to more individuals and healthcare providers and to support programmes such as personalised recovery and return-to-work interventions. Perci highlights measurable clinical and cost-efficiency impacts as part of its case for broader adoption across health systems. Perci Health operates a specialized digital platform that connects people living with and beyond cancer, and their caregivers, to vetted cancer professionals through personalized programs. The platform covers the full cancer continuum, from preparing for treatment to support during treatment, recovery, rehabilitation and return to work. Programs are delivered digitally and tailored to individual needs. The company intends to use new funding to further invest in its technology roadmap, continue to expand the team and grow access through new partnerships. Perci recently closed a Seed round to support these plans. Perci Health claims to be the world’s first online platform giving people access to support from multidisciplinary cancer teams. The service connects clients with vetted cancer professionals — dietitians, physiotherapists, psychologists, sexual medicine practitioners — all with a minimum of three years of cancer experience. Users can browse trusted articles, book a free session with a Perci Expert (trained cancer nurses), and receive a personalised care plan that can be shared with their medical team. The startup emphasizes evidence-based, research-backed care rather than alternative therapies and is governed by leading UK oncologists and cancer surgeons. Perci’s mission is to make affordable, high-quality cancer care more accessible and to challenge the status quo for people living with and beyond cancer. The company launched with seed funding to support its growth and service rollout.

Participated · Equity · Feb 2025

Dxcover develops the PANAROMIC™ Platform and MOSA-Dx™ multiomic spectral analysis approach to enable early detection of solid tumor cancers from minute liquid biopsy samples. The platform uses AI-driven analysis and reports results with a one-day turnaround, supported by data from over 9,000 patients and 250,000 spectra to tune sensitivity and specificity. Dxcover’s technology is globally patented and intended to provide rapid, clinician-actionable results to improve patient management. With the new $6.2M investment (bringing total funding to $21.4M since its 2019 spinout), the company will further advance its proprietary technologies and scale operations. Plans include expanding into new markets and indications, commercializing a Brain Cancer Liquid Biopsy across the UK and Europe, and establishing a US headquarters in Nashville following US incorporation in 2024. Recent senior leadership appointments (co-founders as CSO and CTO and a General Manager for UK/US sites) are aimed at accelerating commercialization and international growth. Dxcover develops a liquid biopsy platform that uses infrared spectroscopy of blood samples combined with AI algorithms to detect pan-omic biomarkers for early-stage cancers. The company has generated clinical data showing high-accuracy detection of Stage I and Stage II cancers and expanded its technology to eight cancers in 2022. The funding announced will accelerate development and commercialization of organ-specific tests, beginning with brain cancer and expanded colorectal cancer programs. Dxcover plans a multicenter study toward CE IVDR marking for its Brain Cancer test and will continue collaborative projects to broaden its pipeline. The company was formed in 2019 and is based in Scotland, United Kingdom, while expanding its network in Europe and the USA. Financially, Dxcover announced $11.9M in combined Series A and grant financing to support these activities. ClinSpec Diagnostics is a Glasgow spinout from the Department of Pure and Applied Chemistry at the University of Strathclyde. Led by CEO Mark Hegarty, the company develops a liquid-biopsy blood test for early cancer detection that combines infra-red light and artificial intelligence, based on research by Dr Matthew Baker. The technology is intended as a minimally invasive assay for early detection of cancer. ClinSpec has received grant funding from the Higgs EDGE Special Award and Innovate UK through the precision medicine accelerator fund. It completed seed funding in 2019 and subsequent financing tranches, and has raised £5.1m to date. Following the latest investment, Prof David Onions of Norcliffe Capital joined ClinSpec’s board of directors. ClinSpec Diagnostics develops a multi-cancer early detection test based on a simple blood assay, spun out from the University of Strathclyde. Led by CEO Mark Hegarty, the company has run studies on brain, prostate and pancreatic cancers. It intends to use the funding to progress its multi-cancer development program, complete a second brain cancer trial, and develop a multi-cancer algorithm covering the most common cancers. The company plans to hire five more employees to strengthen scientific and operations teams, bringing headcount to fourteen. ClinSpec was established in 2016 and has raised grant funding from the Higgs EDGE Special Award and Innovate UK alongside prior seed investment. ClinSpec Diagnostics is advancing a blood test that can provide accurate results in ten minutes and aims to improve brain cancer survival through earlier detection. The technology uses infra-red light combined with machine learning and is based on research by Dr Matthew J. Baker at the University of Strathclyde. The company has demonstrated the brain cancer test’s potential in a clinical study at Edinburgh’s Western Infirmary. ClinSpec plans to further develop its brain cancer test and begin work on tests for prostate and pancreatic cancer. Management is led by CEO Dr Mark Hegarty. The firm says the technology also has applications beyond medicine, including testing in the food, drug and oil industries. Financially, the company has secured multiple funding sources to support development and hiring plans.

Participated · Series A · Jan 2025

Oxford Cancer Analytics (OXcan) is a medtech company developing protein-based blood tests for early cancer detection using advanced proteomics, explainable machine learning, and AI. Its core product is a protein-based liquid biopsy intended to identify molecular signatures in high-risk lung cancer patients with high accuracy and localization capacity. OXcan leverages a diverse global biobank and, since 2023, has partnered with over 20 healthcare centers across three continents to develop and deploy its technology. The company has achieved ISO13485 certification and describes the test as affordable, minimally invasive, and suitable for routine population screening. OXcan plans to use new funding to develop and globally commercialize its next-generation lung cancer blood tests. It recently raised US$11 million in a Series A and appointed Dr. Heinrich Roder as Senior Vice President of R&D to advance its lung cancer blood test toward deployment.

Participated · Equity · Dec 2024

52North is a Cambridge, UK-based med-tech company developing low-cost products to streamline urgent care pathways in oncology and improve patient safety across socio-economic groups. Its flagship product, Neutrocheck®, was granted breakthrough status by the UK Government under the Innovative Devices Access Pathway earlier this year. The company's products are still in development, have not been authorised by regulators and are not currently available for sale. 52North plans to use the £4.72M in newly raised funding to advance its products toward market. Founded in 2018 by University of Cambridge postgraduates, the company focuses on urgent care pathways in oncology. 52North, founded in 2018 and based in Cambridge, develops Neutrocheck, a portable device plus app that enables cancer patients to test their risk of life-threatening neutropenic sepsis at home or in clinical settings. The company’s mission is to improve health outcomes and health equity by reinventing care pathways. 52North was named Medtech Company of the Year at the 2023 Cambridge Independent Science & Technology Awards. It has joined two major US accelerator programmes — Cedars‑Sinai and Texas Medical Centre — and is participating in a US incubator to drive international expansion. Participation in those programmes, funded in part by Innovate UK’s Global Business Incubator programme, has included over 50 mentor interactions with clinicians and insurers to refine the US value proposition. The company has engaged in industry events and collaborations, including presentations at HLTH and the Texas Life Sciences Forum and a new collaboration with Cedars‑Sinai’s Tatonetti Lab; financially it received a $100,000 investment from Cedars‑Sinai alongside other investors. Founded in 2018 and based in the UK, 52 North Health has developed NeutroCheck, a small portable device paired with a digital platform that assesses neutropenic sepsis risk from a blood finger-prick. The solution aims to triage patients at home so at-risk patients are prioritised for urgent care while low-risk patients can avoid unnecessary A&E visits. The company plans to incorporate UnifAI Technology’s AI-powered digital reader into the solution and to progress through its first clinical trial. With a new grant from Innovate UK, the startup will scale development, hit key clinical milestones and prepare for clinical validation. The clinical validation study is expected to begin next summer and involve about 250 patients, followed by an at-home test of the device for around 30 patients. Results will support a regulatory submission for UKCA and CE marking and build evidence to enable NHS roll-out. 52 North Health developed NeutroCheck, a low-cost clinical AI point-of-care device and digital platform for at-home monitoring of neutropenic sepsis risk in cancer patients. The company says NeutroCheck improves safety, quality of life and care pathways by enabling remote monitoring and AI-driven risk prediction. Its platform combines patient and clinician input with predictive models to inform treatment decisions. The startup is women-led and founded in 2018 at the GPS coordinates of Cambridge. 52 North plans to use its recent funding to advance NeutroCheck through U.K. clinical trials and to pursue strategic partnerships with organisations such as the UK Sepsis Trust and Macmillan Cancer Support. The company positions health equity and improved outcomes at the heart of its solutions.